There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis. In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

Cognitive symptoms, mood disorders, and fatigue manifest differently in relapsing-remitting vs. progressive forms of MS, a ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

A newly developed AI correctly judged with 90% accuracy when a person’s MS had transitioned to a stage where it will progress ...

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis, researchers reported in the New England ...

SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis ...

Get Instant Summarized Text (Gist) An AI model using clinical data from over 22,000 patients can identify the transition from relapsing-remitting to secondary progressive multiple sclerosis (MS ...